Patient/caregiver was instructed upon therapeutic uses and mechanism of action of Requip as follows:
- Low levels of the neurotransmitter dopamine and consequent reduced stimulation of dopaminergic receptors in the brain and nervous tissues, result in development of symptoms of Parkinson’s disease.
- Requip belongs to a class of medications called dopamine agonists, which act in place of dopamine at the dopaminergic receptors.
- Requip potentiates/increases the stimulation of dopaminergic receptors in the brain and nervous tissues.
- Potentiation of dopaminergic receptors in the nervous tissues by Requip intake contributes to relief and management of symptoms of Parkinson’s disease.
- Requip, by potentiating dopaminergic action can also help with management of symptoms of restless leg syndrome.
